Mural Oncology plc Files 8-K with Multiple Material Events
| Field | Detail |
|---|---|
| Company | Mural Oncology PLC |
| Form Type | 8-K |
| Filed Date | Dec 5, 2025 |
| Risk Level | high |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.01 M, $0.01, $2.035 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, delisting, corporate-governance, change-of-control
TL;DR
Mural Oncology 8-K: Big changes happening - acquisition, delisting risk, control shifts, exec changes. Stay tuned.
AI Summary
Mural Oncology plc filed an 8-K on December 5, 2025, reporting several material events. These include the completion of an acquisition or disposition of assets, notice of delisting or failure to meet listing rules, material modifications to security holder rights, changes in control, departure/election of officers and directors, amendments to articles of incorporation, and other events. The company, formerly known as Mural Oncology Ltd and Pistachiovale Ltd, is incorporated in L2 with its fiscal year ending December 31.
Why It Matters
This 8-K filing indicates significant corporate actions and potential changes for Mural Oncology plc, which could impact its stock listing, control, and operational structure.
Risk Assessment
Risk Level: high — The filing indicates potential delisting, changes in control, and significant corporate actions, all of which carry substantial risk.
Key Numbers
- 20251205 — Report Date (Date of the 8-K filing and earliest event date.)
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Mural Oncology plc (company) — Registrant
- Mural Oncology Ltd (company) — Former company name
- Pistachiovale Ltd (company) — Former company name
- 0001971543 (company) — Central Index Key
FAQ
What specific assets were acquired or disposed of by Mural Oncology plc?
The filing does not specify the details of the asset acquisition or disposition, only that it is an item of report.
What are the reasons for the notice of delisting or failure to satisfy listing rules?
The filing lists 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing' as an item of report, but does not provide the specific reasons.
What triggered the material modifications to the rights of security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an event, but the specific modifications are not detailed in the provided text.
What changes in control of Mural Oncology plc are being reported?
The filing lists 'Changes in Control of Registrant' as an item of report, but the details of any such changes are not provided.
Which officers or directors have departed or been appointed, and what compensatory arrangements are involved?
The filing mentions 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as an item, but does not name individuals or detail arrangements.
Filing Stats: 1,820 words · 7 min read · ~6 pages · Grade level 12 · Accepted 2025-12-05 08:22:59
Key Financial Figures
- $0.01 M — istered Ordinary Shares, nominal value $0.01 MURA The Nasdaq Global Market Indicate
- $0.01 — standing ordinary shares, nominal value $0.01 per share, of the Company (the "Ordinar
- $2.035 — ive Time, obtained the right to receive $2.035 in cash (the "Scheme Consideration") in
Filing Documents
- d64366d8k.htm (8-K) — 42KB
- d64366dex31.htm (EX-3.1) — 370KB
- d64366dex991.htm (EX-99.1) — 12KB
- g64366dsp050.jpg (GRAPHIC) — 134KB
- g64366g1205044911525.jpg (GRAPHIC) — 4KB
- 0001193125-25-308710.txt ( ) — 811KB
- mura-20251205.xsd (EX-101.SCH) — 3KB
- mura-20251205_lab.xml (EX-101.LAB) — 18KB
- mura-20251205_pre.xml (EX-101.PRE) — 11KB
- d64366d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1+ Transaction Agreement, dated August 20, 2025, by and among XOMA Royalty Corporation, XRA 5 Corp. and Mural Oncology plc (incorporated by reference to Exhibit 2.1 to the registrant's Current Report on Form 8-K filed on August 20, 2025). 2.2+ Appendix I to Rule 2.7 Announcement, dated as of August 20, 2025 (incorporated by reference to Exhibit 2.2 to the registrant's Current Report on Form 8-K on August 20, 2025). 3.1* Amended Memorandum and Articles of Association of the Company. 99.1* Press Release of the Company issued on December 5, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Certain schedules and annexes have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted schedules and annexes upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any annexes or schedules so furnished. * Filed herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mural Oncology plc Date: December 5, 2025 By: /s/ Owen Hughes Owen Hughes Chief Executive Officer and Secretary